Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen Inc (NASDAQ: OCGN) rises sharply after announcing the sale of 3 million common shares at $7.65 per share in a registered direct offering, with gross proceeds of $23 million. The offer price represents a premium of 46% on the last close price of $5.25 on Friday.
https://www.nasdaq.com/articles/ocu...ion-ocu400-advanced-therapy-medicinal-product How they've fallen! Last post in 2021, at a time when the stock price was bouncing around $8. The above article is citing some good news for the company, which is now trading at around 70 cents.
Wallbox quarterly revenue 50million Quarterly financials OCGN (USD) Sep 2024 Y/Y Revenue 1.14M 69.29% Net income -12.97M 10.69% Diluted EPS - - Net profit margin -1,141.73% 260.44%
I am not investing in OCGN, nor suggesting anyone else invest in it. I was making an observation about the company, since I came across this thread and decided to look up what had happened in the 3+ years since the last post in this thread.
